Breaking News

Breaking news filtered in real-time to show only the most impactful headlines for US-listed public companies.

SOC Investors Have Opportunity to Lead Sable Offshore Corp. Securities Lawsuit Filed by The Rosen Law Firm

(NYSE:SOC) NEW YORK, Aug. 31, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sable Offshore Corp. (NYSE: SOC): (1) between May 19, ...

Could the lawsuit result in significant financial penalties or a settlement that would impact SOC’s balance sheet and future earnings? What is the expected timeline for the lawsuit's resolution and how might it affect the company’s operations? What potential impact could the securities lawsuit have on SOC's stock price in the short term?
Symbol: SOC
Lawsuits
16 days ago
Read more prnewswire

SLQT Investors Have Opportunity to Lead SelectQuote, Inc. Securities Fraud Lawsuit

(NYSE:SLQT) NEW YORK, Aug. 31, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of SelectQuote, Inc. (NYSE: SLQT) between September 9, 2...

When is the deadline for investors to file claims or opt‑out, and how might that timeline influence market dynamics? What is the estimated potential liability and exposure for SelectQuote from this class action? How will the securities fraud lawsuit affect SelectQuote's upcoming earnings and stock performance?
Symbol: SLQT
Lawsuits
16 days ago
Read more prnewswire

BlackRock Becomes the Second-Largest Shareholder of Freedom Holding Corp.

(NASDAQ:FRHC) NEW YORK, Aug. 31, 2025 /PRNewswire/ -- Freedom Holding Corp. (NASDAQ: FRHC), a global financial services and technology company, announced that the world's largest investment company...

Are there any risks of downside dilution or margin calls that could affect the $89 million investment if FRHC's stock experiences volatility? What does BlackRock's ownership level reveal about the firm's valuation and potential for future strategic partnership or board influence? How will BlackRock's increased stake influence Freedom Holding Corp's liquidity and short‑term price movement?
Symbol: FRHC
Investments
16 days ago
Read more prnewswire

New Data from the DanGer Shock Randomized Control Trial, Published in The New England Journal of Medicine, Confirms the Long-Term Survival Benefit of the Impella CP Heart Pump

(NYSE:JNJ) MADRID, Aug. 31, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) – Late breaking clinical science data, presented at the European Society of Cardiology (ESC) Congress today and simult...

Will the positive trial results trigger any regulatory approvals, insurance coverage changes, or partnership activity that could drive a material change in JNJ’s valuation? What pricing, reimbursement, and adoption hurdles could limit the commercial upside of the Impella CP compared with competing mechanical circulatory support devices? How will the new long‑term survival data for the Impella CP affect Johnson & Johnson’s cardiovascular device revenue forecasts and earnings guidance?
Symbol: JNJ
Clinical trials
16 days ago
Read more prnewswire

Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025

(NASDAQ:KRT) Additional Data from MAPLE-HCM Shows Aficamten Improves Cardiac Structure and Function Compared to Metoprolol; Simultaneous Publication in the Journal of the American College of Cardio...

What is the anticipated timeline for regulatory approval, commercial launch, and reimbursement for aficamten, and what are the potential risks to that timeline? What are the comparative efficacy and safety profiles of aficamten versus existing HCM therapies such as mavacamten and beta‑blockers, and how might this influence market share? How will the MAPLE‑HCM data and the JACC publication affect Cytokinetics' valuation and short‑term stock volatility?
Symbol: KRT
Clinical trials
16 days ago
Read more globenewswire

Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress

(TBIO) Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress

What are the next regulatory and commercialization milestones (e.g., Phase 3 initiation, FDA/EMA interactions) and their timing implications for long‑term shareholder value? What are the key efficacy and safety endpoints reported, and how do they compare to existing therapies or competing pipeline candidates? How will the Phase 2 TRANQUILITY trial results influence TBIO's valuation and near‑term stock price?
Symbol: TBIO
Clinical trials
16 days ago
Read more globenewswire